Supernus Pharmaceuticals Inc. (SUPN) Given a $28.00 Price Target by Jefferies Group Analysts
Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) received a $28.00 price objective from investment analysts at Jefferies Group in a report released on Thursday. The firm presently has a a “buy” rating on the specialty pharmaceutical company’s stock. Jefferies Group’s price target points to a potential upside of 29.99% from the stock’s current price.
Several other equities analysts have also recently commented on SUPN. Zacks Investment Research upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $23.00 price target on the stock in a report on Wednesday, July 6th. Piper Jaffray Cos. cut shares of Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and set a $23.00 price objective for the company. in a report on Monday, July 18th. Finally, Northland Securities cut shares of Supernus Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $24.00 price objective for the company. in a report on Monday, July 18th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $25.25.
Supernus Pharmaceuticals (NASDAQ:SUPN) traded up 2.484% during trading on Thursday, reaching $22.075. The company had a trading volume of 769,114 shares. Supernus Pharmaceuticals has a 12-month low of $9.51 and a 12-month high of $26.84. The firm has a 50-day moving average price of $23.58 and a 200 day moving average price of $20.23. The stock has a market cap of $1.09 billion, a P/E ratio of 45.051 and a beta of 1.73.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/13/supernus-pharmaceuticals-inc-supn-given-a-28-00-price-target-by-jefferies-group-analysts.html
Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings results on Tuesday, August 2nd. The specialty pharmaceutical company reported $0.18 EPS for the quarter, beating the consensus estimate of $0.13 by $0.05. Supernus Pharmaceuticals had a net margin of 14.94% and a return on equity of 20.99%. The business had revenue of $50.40 million for the quarter, compared to analysts’ expectations of $49.67 million. During the same period in the previous year, the company posted $0.03 EPS. Supernus Pharmaceuticals’s revenue was up 43.6% on a year-over-year basis. Equities research analysts predict that Supernus Pharmaceuticals will post $0.68 EPS for the current fiscal year.
In other Supernus Pharmaceuticals news, CFO Gregory S. Patrick sold 2,000 shares of the business’s stock in a transaction on Friday, September 16th. The shares were sold at an average price of $25.00, for a total transaction of $50,000.00. Following the completion of the transaction, the chief financial officer now owns 3,616 shares of the company’s stock, valued at approximately $90,400. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 6.10% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SUPN. BlackRock Fund Advisors raised its position in Supernus Pharmaceuticals by 9.6% in the second quarter. BlackRock Fund Advisors now owns 3,099,268 shares of the specialty pharmaceutical company’s stock worth $63,132,000 after buying an additional 272,279 shares in the last quarter. Vanguard Group Inc. raised its position in Supernus Pharmaceuticals by 10.0% in the second quarter. Vanguard Group Inc. now owns 1,956,476 shares of the specialty pharmaceutical company’s stock worth $39,854,000 after buying an additional 177,648 shares in the last quarter. Bank of New York Mellon Corp raised its position in Supernus Pharmaceuticals by 34.3% in the second quarter. Bank of New York Mellon Corp now owns 1,659,604 shares of the specialty pharmaceutical company’s stock worth $33,806,000 after buying an additional 423,835 shares in the last quarter. Acadian Asset Management LLC raised its position in Supernus Pharmaceuticals by 4.7% in the second quarter. Acadian Asset Management LLC now owns 1,527,277 shares of the specialty pharmaceutical company’s stock worth $31,110,000 after buying an additional 67,870 shares in the last quarter. Finally, Fiera Capital Corp purchased a new position in Supernus Pharmaceuticals during the second quarter worth $27,544,000. 94.66% of the stock is owned by hedge funds and other institutional investors.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR).
Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.